AMEX · Biotechnology

OS Therapies Incorporated (OSTX) Stock

$1.62 +0.00% AMEX: OSTX Healthcare

Valuation

MetricValue
Price$1.62
Market Cap$73.77M
P/E Ratio-1.42
P/B Ratio-6.28
P/S Ratio0.00
EPS (TTM)$-0.30
52-Week High$2.57
52-Week Low$1.15
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE683.03%
ROA-397.78%
ROCE350.07%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio54.12

Annual Financials (USD)

Metric20212022202320242025
Revenue$0$0$0$0$0
Operating Profit$-5.0M$-4.0M$-4.0M$-7.0M$-29.0M
Net Profit$-7.0M$-6.0M$-8.0M$-9.0M$-29.0M
EPS$-0.33$-0.28$-0.39$-0.52$-0.98
Op Margin—————

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$0$1.0M$1.0M$6.0M$7.0M
Total Liabilities$12.0M$18.0M$25.0M$5.0M$13.0M
Cash$0$0$0$6.0M$0
Borrowings$7.0M$10.0M$15.0M$0$0

Latest News

OS Therapies Accepts New FDA Meeting Request to Review Biomarker Data as Part of BEST Program TMX Newsfile · Jul 8, 2026 OS Therapies Third Quarter 2026 Corporate Outlook TMX Newsfile · Jul 6, 2026 OS Therapies Appoints Dr. Craig Eagle to Board of Directors TMX Newsfile · Jul 2, 2026 OS Therapies Provides U.S. Regulatory Update TMX Newsfile · Jun 30, 2026 OS Animal Health Announces Peer-Reviewed Publication of Clinical Trial Data for OST-HER2 Plus Palliative Radiation as Frontline Treatment in Canine Osteosarcoma TMX Newsfile · Jun 26, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$-4.0M$-4.0M$-3.0M$-7.0M$-14.2B
Investing Cash Flow$0$0$0$0$-467.0M
Financing Cash Flow$0$0$0$31.0M$9.4B
Net Cash Flow$-1.0M$0$0$5.0M$-5.3B
Free Cash Flow$-4.0M$-4.0M$-3.0M$-7.0M$-14.2B

Valuation & Return Ratios

MetricValue
PEG Ratio0.02
EV / EBITDA-1.82
FCF Yield-26.26%
Quick Ratio0.18
Interest Coverage-464.76
Return 1Y-0.63%
Return 3Y—
Return 5Y—

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
ADAGAdagene Inc. $3.67 +1.66% -7.78 $138.17M 0.00%
COEPCoeptis Therapeutics Holdings, Inc. $10.99 -8.57% -4.45 $38.62M 0.00%
CRVOCervoMed Inc. $3.22 -1.83% -0.94 $29.81M 0.00%
EQEquillium, Inc. $1.41 -2.08% -5.50 $89.15M 0.00%
HOWLWerewolf Therapeutics, Inc. $0.98 +7.65% -1.26 $47.61M 0.00%

About OS Therapies Incorporated

OS Therapies Incorporated is led by CEO Paul A. Romness, employs 4 people, headquartered in US, publicly traded since 2024.

OS Therapies Incorporated (OSTX) stock trades at $1.62 with a market capitalization of $73.77M. The stock is valued at a price-to-earnings (P/E) ratio of -1.42, price-to-book of -6.28, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.15 and $2.57, and currently trades 37.0% below its 52-week high.

On profitability, OS Therapies Incorporated generates a return on equity (ROE) of 683.03% — well above the market average, a sign of a high-quality business, return on capital employed of 350.07%, an operating margin of 0.00%, a net profit margin of 0.00%.

Related Healthcare Stocks

LLY Eli Lilly and Company $1179.27 +0.83% JNJ Johnson & Johnson $261.44 +1.93% ABBV AbbVie Inc. $276.47 +1.49% MRK Merck & Company, Inc. Common Stock (new) $145.60 +2.26% UNH UnitedHealth Group Incorporated Common Stock (DE) $379.30 +2.25% NVS Novartis AG $143.75 +0.45% AZN AstraZeneca PLC $159.20 +0.26% TMO Thermo Fisher Scientific Inc $658.02 +0.93% AMGN Amgen Inc. $414.87 +1.82% GILD Gilead Sciences, Inc. $151.17 +2.77% ABT Abbott Laboratories $99.60 +1.13% NVO Novo Nordisk A/S $38.64 +1.20%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksAll stock screens
Run Stock Screener Investing Guides